XJPX
2689
Market cap71mUSD
Oct 09, Last price
1,904.00JPY
1D
-0.05%
1Q
-1.60%
Jan 2017
57.23%
IPO
346.95%
Name
OLBA Healthcare Holdings Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
OLBA HEALTHCARE HOLDINGS, Inc., founded in 1921 and based in Okayama, Japan, provides an extensive range of healthcare and life science solutions to a diverse clientele across the country. Its customers include medical facilities, academic institutions, corporate research laboratories, individuals, and elderly care providers. The company's operations span several key areas. Its Medical Equipment business acts as a wholesale distributor for a wide array of advanced medical devices. This includes prosthetic and implantable items such as artificial joints, pacemakers, and coronary stents; surgical tools like steel instruments and ultrasonic scalpels; and diagnostic imaging systems such, as MRI and CT scanners. Additionally, they supply essential hospital equipment, including respirators, intraoperative monitors, and surgical lighting. In the realm of life sciences, OLBA HEALTHCARE offers specialized reagents and apparatus for genetic research, cell culture, and protein analysis. They also provide automated analyzers for biochemistry, immunology, and blood diagnostics, along with various testing reagents. Furthermore, the company performs dedicated DNA analysis services. The Supply Processing and Distribution (SPD) business supports clients by managing inventory, information, and procurement functions efficiently. Finally, the Nursing Care Products business focuses on enhancing the well-being of those requiring care. This segment offers rental services for nursing care equipment and sells welfare aids such as portable toilets and bathing solutions. They are also involved in managing a program designed to facilitate comfortable long-term care at home, referred to as "long-term care reform." The company rebranded from Kawanishi Holdings, Inc. to OLBA HEALTHCARE HOLDINGS, Inc. in January 2021.
Key people
Toshiyuki Maeshima
Non-Executive Chairman of the Board · since 2018
Yohei Maeshima
President, Chief Executive Officer, Representative Director · since 2015
Yosuke Nose
Vice Chairman of the Board, Chairman of Subsidiary · since 2012
Kyosuke Isoda
Senior Managing Director, Chief Director of Corporate Planning · since 2022
Tatsuya Maeshima
Senior Managing Executive Officer, Manager of Business Planning Office, Director · since 2012
Masahiro Tano
Senior Managing Executive Officer, Director of General Affairs, President of Subsidiary, Director · since 2010
Katsuyuki Kuwamura
Managing Director, Chief Director of Sales · since 2022
Hajime Kawata
Executive Officer, Chief Director of Administration, Director · since 2012
Keiji Omote
Executive Officer
Nobuharu Murata
Managing Director, Chief Director of Administration · since 2017
Takeshi Fukuyama
Independent Director · since 2007
Teruhiko Hattori
Independent Director · since 2016
Yukiko Kawamoto
Independent Director · since 2018
Yukihiro Kitagawa
Independent Director · since 2020
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||